Health
A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity – News-Medical.Net
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome…
As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
New approaches to spike-based vaccines
Both the viral spike antigen and its receptor-binding domain (RBD), which elicit highly potent neutralizing…
-
Noosa News15 hours agoHow Lily Steele-Park took her rapist to court and won
-
General21 hours agoRush to buy homes before rate cuts send prices soaring
-
Business17 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Business20 hours agoFord CEO makes stunning prediction about artificial intelligence